Seelos Forges Ahead With SLS-002, Says Primary Endpoint Miss Due To Underpowered Trial

 
• By Alaric DeArment
  
Seelos plans to move ahead with SLS-002's development despite a primary endpoint miss in a Phase II study • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D